Zhe-Sheng (Jason) Chen
Basic info is private.
Interests
Cancer pharmacology; Drug discovery; Multidrug resistance (MDR)
Latest Publications
- Open Access Original ResearchABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1Zhuoxun Wu, Yuqi Yang, Zining Lei, Silpa Narayanan, ... Zhesheng ChenFront. Biosci. (Landmark Ed) 2022, 27(1), 5; https://doi.org/10.31083/j.fbl270100587Downloads3Citations345Views
- Open Access Original ResearchPoly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancersNarayanan Silpa, Teng Qiu-Xu, Koya Jagadish, Wang Jingquan, ... Chen Zhe-ShengJ. Mol. Clin. Med. 2019, 2(3), 55–67; https://doi.org/10.31083/j.jmcm.2019.03.030391Downloads5Citations173Views
- Open Access Original ResearchKIT and PDGFRA inhibitor avapritinib (BLU-285) overcomes ABCB1- and ABCBG2-mediated MDR in cancer cellsGupta Pranav, V. Ashar Yunali, Teng Qiu-Xu, Lei Zining, ... Chen Zhe-ShengJ. Mol. Clin. Med. 2019, 2(3), 69–78; https://doi.org/10.31083/j.jmcm.2019.03.030122Downloads79Views